Precision for Medicine Acquires Epiontis, Adding Epigenetic Expertise

October 4, 2017

Precision for Medicine has acquired Epiontis for an undisclosed price, in a deal designed to add epigenetic expertise and an expanded global presence to the buyer’s precision medicine capabilities.

Berlin-based Epiontis is a specialty laboratory that has developed a novel, patent-protected epigenetic platform, through which it offers an immune cell monitoring service as well as customized development of epigenetic assays.

Founded in 2003, Epiontis offers validated epigenetic immune cell assays for clinical trial immune monitoring, including diagnostic assays for regulatory T cells (Tregs) and tumor infiltrating lymphocytes. The company says its epigenetic assay format allows for identification and quantification of any cell type with accuracy and technical ease—focused mainly on immune cells in research and clinical studies for autoimmune and infectious diseases or cancer.

Epiontis says it serves 17 of the top 20 global pharmaceutical companies, while contributing expertise to nearly 100 clinical trials heavily focused on autoimmune disorders and immuno-oncology.

“Becoming part of Precision allows us to provide our clients with a complete, customized immune monitoring solution, and also gives us the opportunity to introduce our proprietary epigenetic technology and expertise to a broader customer base,” Sven Olek, Ph.D., Epiontis co-founder and CEO, said in a statement. “Together, Precision and Epiontis are able to offer innovative life sciences clients many options for immune monitoring, including our patented epigenetic markers and global flow cytometry capabilities.”

Precision for Medicine, which provides a suite of immune monitoring services for clinical trials, said the acquisition is aimed at bringing additional value to its clients by enhancing its scientific offerings in precision medicine on a global scale.

Immune monitoring solutions to be offered by Epiontis with Precision will cover a broad range from preclinical through Phase III clinical, with assays ranging across platforms that include flow cytometry, ELISpot, and multiplex cytokine profiling.

"The acquisition of Epiontis allows Precision to significantly expand upon our immune monitoring capabilities, and their technology provides a faster, economically viable, and easier global solution for immune monitoring under a variety of scenarios," said Precision for Medicine President Chad Clark.

Additionally, Clark said Epiontis offers Precision for Medicine with an additional base for European operations—the acquired company is headquartered at the Science and Technology Park within Berlin Adlershof Science City—at a time when the company is focused on expanding globally. Precision for Medicine and its Precision Oncology CRO have expanded their presence in Europe, with Precision opening a European headquarters in Paris and an office in Edinburgh, Scotland.